Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)

por Frey, Reiner, Mück, Wolfgang, Kirschbaum, Nina, Krätzschmar, Jörn, Weimann, Gerrit, Wensing, Georg
Publicado 2009

Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure

por Mitrovic, Veselin, Swidnicki, B, Ghofrani, Ardeschir, Mück, Wolfgang, Kirschbaum, Nina, Mittendorf, Joachim, Stasch, Johannes-Peter, Wensing, Georg, Frey, Reiner, Lentini, Silvia
Publicado 2009

A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease

por Filippatos, Gerasimos, Anker, Stefan D., Böhm, Michael, Gheorghiade, Mihai, Køber, Lars, Krum, Henry, Maggioni, Aldo P., Ponikowski, Piotr, Voors, Adriaan A., Zannad, Faiez, Kim, So-Young, Nowack, Christina, Palombo, Giovanni, Kolkhof, Peter, Kimmeskamp-Kirschbaum, Nina, Pieper, Alexander, Pitt, Bertram
Publicado 2016